Arcus Biosciences (RCUS) Projected to Post Earnings on Wednesday

Key Points

• Arcus Biosciences is expected to release its Q2 2025 earnings report on August 6th, with analysts predicting a loss of ($1.14) per share and revenue of $32.86 million for the quarter.
• The company's previous earnings report showed a 80.7% decline in revenue year-over-year, posting earnings of ($1.14) per share, which missed consensus estimates by ($0.12).
• Analysts have varied price targets for Arcus Biosciences, with some lowering targets significantly, while others maintain positive ratings, resulting in a consensus rating of "Moderate Buy" and a price target of $21.29.

Arcus Biosciences (NYSE:RCUS - Get Free Report) is projected to post its Q2 2025 quarterly earnings results after the market closes on Wednesday, August 6th. Analysts expect Arcus Biosciences to post earnings of ($1.14) per share and revenue of $32.86 million for the quarter.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.12). Arcus Biosciences had a negative net margin of 258.94% and a negative return on equity of 70.58%. The firm had revenue of $28.00 million during the quarter, compared to analyst estimates of $38.61 million. During the same period in the previous year, the company posted ($0.05) EPS. Arcus Biosciences's revenue for the quarter was down 80.7% compared to the same quarter last year. On average, analysts expect Arcus Biosciences to post $-3 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Arcus Biosciences Stock Performance

Shares of Arcus Biosciences stock traded up $0.03 on Friday, hitting $9.16. The stock had a trading volume of 805,025 shares, compared to its average volume of 701,151. Arcus Biosciences has a twelve month low of $6.50 and a twelve month high of $18.98. The business's 50 day moving average is $9.13 and its two-hundred day moving average is $9.60. The company has a quick ratio of 5.37, a current ratio of 5.37 and a debt-to-equity ratio of 0.09. The stock has a market cap of $969.95 million, a price-to-earnings ratio of -2.19 and a beta of 0.89.

Hedge Funds Weigh In On Arcus Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC increased its stake in shares of Arcus Biosciences by 29.2% in the 1st quarter. Millennium Management LLC now owns 1,194,622 shares of the company's stock valued at $9,378,000 after purchasing an additional 270,253 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Arcus Biosciences by 106.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company's stock valued at $7,177,000 after purchasing an additional 470,755 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Arcus Biosciences by 253.9% in the 1st quarter. AQR Capital Management LLC now owns 90,954 shares of the company's stock valued at $714,000 after purchasing an additional 65,254 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Arcus Biosciences by 10.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,572 shares of the company's stock valued at $297,000 after purchasing an additional 3,565 shares during the last quarter. Finally, Strs Ohio bought a new position in shares of Arcus Biosciences in the 1st quarter valued at $67,000. Institutional investors own 92.89% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Wedbush reaffirmed an "outperform" rating and issued a $33.00 target price on shares of Arcus Biosciences in a research report on Wednesday, May 7th. Morgan Stanley reduced their price target on Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. Wells Fargo & Company reduced their price target on Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. The Goldman Sachs Group reduced their price target on Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Finally, Barclays reduced their price target on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 23rd. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $21.29.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.